Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy

Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy

Sep 24, 2020
|
staff reporter

NEW YORK – San Francisco-based Calithera Biosciences on Thursday said that it had dosed the first patient in a Phase II clinical trial of its investigational agent telaglenastat plus chemotherapy and the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line advanced, KEAP1- or NRF2-mutated non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Featured Webinar

The Tumor Neighborhood Watch: How Spatial Architecture and Cellular Neighborhoods Correlate to Colorectal Cancer Outcomes

Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

What's Popular?

In Cancer

  1. Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC

  2. Early Data in Hand, Verastem Marches Ahead With RAF-MEK Inhibitor Program in KRAS-mutated Cancers

    Premium

  3. Scorpion Therapeutics Launches With $108 Million in Series A Funding

  4. Epic Sciences, Predicine to Offer Liquid Biopsy Service for Biopharma Customers

  5. SickKids' 'Rigorous' Molecular Analysis IDs Targetable Alterations, Cancer Susceptibility Mutations

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.